Macrocyclic Compounds Blocking PD-L1 Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer and infectious diseases, such as cancer and chronic infections, face challenges in effectively inhibiting the PD-1/PD-L1 interaction, which leads to immune evasion and exhaustion, limiting the efficacy of immune responses.
Innovation Solution
Development of macrocyclic compounds that specifically bind to PD-L1, inhibiting its interaction with PD-1 and CD80, thereby enhancing immune responses and stimulating antigen-specific T cell functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to block PD-1/PD-L1 interaction, then immune response is enhanced, but therapeutic efficacy in cancer and infectious diseases is limited due to immune evasion and exhaustion
Solution Approach 1:
The patent segments the therapeutic approach by developing separate macrocyclic compounds that target different interaction pathways: one compound blocks PD-1/PD-L1 interaction while another blocks PD-L1/CD80 interaction. This segmentation allows simultaneous disruption of multiple immune evasion mechanisms, thereby overcoming the limitations of single-antibody therapies and enhancing overall therapeutic efficacy against cancer and infectious diseases.
2Reliability
If PD-1/PD-L1 interaction is blocked, then T cell activation is restored, but PD-L1 can still interact with CD80 to maintain immune suppression
Solution Approach 1:
The patent introduces a second macrocyclic compound as an intermediary agent that specifically binds to PD-L1 and blocks its interaction with CD80. This intermediary compound works in conjunction with the first compound (which blocks PD-1/PD-L1) to completely prevent PD-L1-mediated immune suppression through both PD-1 and CD80 pathways, thereby fully restoring T cell activation function.
Data Source
AI summary
In accordance with the present disclosure, compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.